ZIOPHARM Oncology Stock Price, News & Analysis (NASDAQ:ZIOP)

$3.83 -0.05 (-1.29 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$3.88
Today's Range$3.80 - $3.95
52-Week Range$3.33 - $7.88
Volume1.25 million shs
Average Volume2.06 million shs
Market Capitalization$543.72 million
P/E Ratio-7.37
Dividend YieldN/A
Beta1.42

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology logoZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone+1-617-2591970

Debt

Debt-to-Equity RatioN/A
Current Ratio6.32%
Quick Ratio6.32%

Price-To-Earnings

Trailing P/E Ratio-7.36538461538462
Forward P/E Ratio-7.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.86 million
Price / Sales79.26
Cash FlowN/A
Price / CashN/A
Book Value($0.59) per share
Price / Book-6.49

Profitability

Trailing EPS($0.52)
Net Income$-165,290,000.00
Net Margins-818.19%
Return on EquityN/A
Return on Assets-47.07%

Miscellaneous

Employees36
Outstanding Shares141,960,000

ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) released its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.13). The biotechnology company earned $1.60 million during the quarter, compared to analysts' expectations of $1.66 million. The firm's quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. View ZIOPHARM Oncology's Earnings History.

When will ZIOPHARM Oncology make its next earnings announcement?

ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for ZIOPHARM Oncology.

Where is ZIOPHARM Oncology's stock going? Where will ZIOPHARM Oncology's stock price be in 2018?

3 Wall Street analysts have issued 12-month price objectives for ZIOPHARM Oncology's shares. Their predictions range from $10.00 to $23.00. On average, they anticipate ZIOPHARM Oncology's share price to reach $16.50 in the next twelve months. View Analyst Ratings for ZIOPHARM Oncology.

Are investors shorting ZIOPHARM Oncology?

ZIOPHARM Oncology saw a decrease in short interest in January. As of January 31st, there was short interest totalling 31,141,614 shares, a decrease of 5.9% from the January 12th total of 33,104,937 shares. Based on an average daily volume of 2,474,487 shares, the days-to-cover ratio is presently 12.6 days. Approximately 24.5% of the company's shares are short sold.

Who are some of ZIOPHARM Oncology's key competitors?

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the folowing people:

  • Laurence James Neil Cooper M.D., Ph.D., Chief Executive Officer (Age 52)
  • Kevin G. Lafond CPA, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 61)
  • David M. Mauney M.D., Interim Chief Operating Officer, Executive Vice President, Chief Business Officer (Age 49)
  • Caesar J. Belbel, Executive Vice President, Chief Legal Officer and Secretary (Age 57)
  • Francois Lebel M.D., Executive Vice President - Research and Development and Chief Medical Officer (Age 65)
  • Lynn Ferrucci, Senior Vice President - Human Resources, Facilities and Administration
  • David Connolly, Vice President - Corporate Communications and Investor Relations
  • Murray Brennan M.D., Non-Executive Lead Independent Director (Age 77)
  • Randal J. Kirk, Director (Age 63)
  • James A. Cannon, Independent Director (Age 78)

Who owns ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.99%), Geode Capital Management LLC (0.82%), Schwab Charles Investment Management Inc. (0.45%), TIAA CREF Investment Management LLC (0.21%), Deutsche Bank AG (0.21%) and Vident Investment Advisory LLC (0.21%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.

Who sold ZIOPHARM Oncology stock? Who is selling ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Belpointe Asset Management LLC, Rhumbline Advisers, Wells Fargo & Company MN and Goldman Sachs Group Inc.. View Insider Buying and Selling for ZIOPHARM Oncology.

Who bought ZIOPHARM Oncology stock? Who is buying ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Deutsche Bank AG, Virtu Financial LLC, Vident Investment Advisory LLC, Virtus Fund Advisers LLC, MetLife Investment Advisors LLC, Ladenburg Thalmann Financial Services Inc. and Metropolitan Life Insurance Co. NY. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.

How do I buy ZIOPHARM Oncology stock?

Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOPHARM Oncology stock can currently be purchased for approximately $3.83.

How big of a company is ZIOPHARM Oncology?

ZIOPHARM Oncology has a market capitalization of $543.72 million and generates $6.86 million in revenue each year. The biotechnology company earns $-165,290,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. ZIOPHARM Oncology employs 36 workers across the globe.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is One First Avenue Parris Building 34 , Navy Yard Plaza, BOSTON, MA 02129, United States. The biotechnology company can be reached via phone at +1-617-2591970 or via email at [email protected]


MarketBeat Community Rating for ZIOPHARM Oncology (ZIOP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ZIOPHARM Oncology (NASDAQ:ZIOP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.50$16.50$16.25$16.50
Price Target Upside: 271.62% upside271.62% upside247.97% upside198.37% upside

ZIOPHARM Oncology (NASDAQ:ZIOP) Consensus Price Target History

Price Target History for ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology (NASDAQ:ZIOP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017HC WainwrightSet Price TargetBuy$10.00MediumView Rating Details
12/11/2017Raymond James FinancialReiterated RatingHoldHighView Rating Details
2/28/2017Griffin SecuritiesReiterated RatingBuy$23.00N/AView Rating Details
1/12/2017JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/10/2016Wells Fargo & CoUpgradeUnderperform -> Market PerformN/AView Rating Details
7/18/2016MizuhoReiterated RatingNeutral$7.00 -> $5.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

ZIOPHARM Oncology (NASDAQ:ZIOP) Earnings History and Estimates Chart

Earnings by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology (NASDAQ ZIOP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018($0.13)N/AView Earnings Details
11/6/2017Q3 2017($0.13)($0.13)$1.66 million$1.60 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.13)($0.13)$1.66 million$1.60 millionViewN/AView Earnings Details
5/1/2017Q1 2017($0.12)($0.15)$1.71 million$1.60 millionViewListenView Earnings Details
2/16/2017Q4 2016($0.11)($0.11)$1.62 million$1.60 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.11)($0.11)$1.45 million$1.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.11)($1.01)$1.52 million$1.70 millionViewN/AView Earnings Details
5/10/2016Q1($0.08)($0.09)$1.89 million$1.97 millionViewN/AView Earnings Details
2/24/2016Q4($0.07)($0.07)$1.82 million$1.92 millionViewN/AView Earnings Details
11/2/2015Q315($0.13)($0.14)$1.19 million$1.90 millionViewN/AView Earnings Details
8/10/2015Q2($0.22)($0.11)$57.70 million$0.27 millionViewN/AView Earnings Details
5/7/2015($0.13)($0.10)$0.20 million$0.30 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.09)$420.00 million$0.34 millionViewN/AView Earnings Details
10/30/2014Q314($0.12)($0.06)$0.20 million$0.63 millionViewN/AView Earnings Details
8/7/2014Q214($0.17)($0.06)$7.50 million$0.20 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.10)$0.20 million$0.20 millionViewN/AView Earnings Details
3/3/2014Q413($0.15)($0.09)$0.20 million$0.20 millionViewN/AView Earnings Details
10/22/2013Q313($0.17)($0.20)$0.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.24)($0.22)$0.20 million$0.20 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.29)($0.48)$0.17 million$0.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.29)ViewN/AView Earnings Details
5/3/2012($0.22)($0.25)ViewN/AView Earnings Details
2/29/2012($0.23)($0.24)ViewN/AView Earnings Details
11/3/2011($0.28)($0.01)ViewN/AView Earnings Details
8/1/2011($0.23)($0.16)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.17)($0.18)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.25)($0.25)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.17)($0.18)ViewN/AView Earnings Details
7/30/2010Q2 2010($0.13)$0.19ViewN/AView Earnings Details
4/30/2010Q1 2010($0.10)($0.11)ViewN/AView Earnings Details
3/18/2010Q4 2009($0.12)$0.03ViewN/AView Earnings Details
11/11/2009Q3 2009($0.13)ViewN/AView Earnings Details
8/14/2009Q2 2009($0.10)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.16)ViewN/AView Earnings Details
3/24/2009Q4 2008($0.19)($0.21)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.23)($0.26)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.36)($0.31)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.35)($0.41)ViewN/AView Earnings Details
2/22/2008Q4 2007($0.39)($0.36)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ZIOPHARM Oncology (NASDAQ:ZIOP) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.56 EPS

Dividends

Dividend History for ZIOPHARM Oncology (NASDAQ:ZIOP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ZIOPHARM Oncology (NASDAQ ZIOP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 40.83%
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology (NASDAQ ZIOP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2017David M Md MauneyEVPBuy4,270$4.68$19,983.6058,662View SEC Filing  
11/8/2017Laurence James Neil CooperCEOBuy6,440$4.68$30,139.201,083,731View SEC Filing  
6/4/2015Murray BrennanDirectorSell40,000$9.70$388,000.00View SEC Filing  
2/9/2015Randal J KirkDirectorBuy1,440,000$8.75$12,600,000.00View SEC Filing  
10/29/2013Randal J KirkDirectorBuy2,857,143$3.50$10,000,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ZIOPHARM Oncology (NASDAQ ZIOP) News Headlines

Source:
DateHeadline
ZIOPHARM Oncology Inc. (ZIOP) Given Consensus Recommendation of "Hold" by BrokeragesZIOPHARM Oncology Inc. (ZIOP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 18 at 1:30 AM
Wired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone SymposiaWired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone Symposia
finance.yahoo.com - February 14 at 3:23 PM
Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference ... - GlobeNewswire (press release)Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 3:21 PM
Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1
finance.yahoo.com - February 13 at 3:21 PM
Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular ... - GlobeNewswire (press release)Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 6:14 AM
Pre-Open Movers 02/12: (CSRA) (HGSH) (COLL) Higher; (AXON) (SPNS) (LJPC) Lower (more...)Pre-Open Movers 02/12: (CSRA) (HGSH) (COLL) Higher; (AXON) (SPNS) (LJPC) Lower (more...)
www.streetinsider.com - February 12 at 3:21 PM
ZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.59 MillionZIOPHARM Oncology Inc. (ZIOP) Expected to Announce Quarterly Sales of $1.59 Million
www.americanbankingnews.com - February 11 at 6:50 AM
ZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 5.9% in JanuaryZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 5.9% in January
www.americanbankingnews.com - February 10 at 1:40 AM
Ziopharm stock rallies after company says nothing to see here, folks - MarketWatchZiopharm stock rallies after company says nothing to see here, folks - MarketWatch
www.marketwatch.com - February 7 at 6:10 AM
Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 GuidanceZiopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance
finance.yahoo.com - February 6 at 3:21 PM
Ziopharm stock rallies after company says nothing to see here, folksZiopharm stock rallies after company says nothing to see here, folks
finance.yahoo.com - February 6 at 3:21 PM
Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM ... - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM ... - PR Newswire (press release)
www.prnewswire.com - February 2 at 3:22 PM
ZIOPHARM Oncology Inc. (ZIOP) Receives Average Recommendation of "Hold" from AnalystsZIOPHARM Oncology Inc. (ZIOP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 24 at 1:44 AM
Did ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) Earnings Growth Outperform The Industry?Did ZIOPHARM Oncology Inc’s (NASDAQ:ZIOP) Earnings Growth Outperform The Industry?
finance.yahoo.com - January 23 at 9:32 AM
Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and ZIOPHARM OncologyToday’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and ZIOPHARM Oncology
finance.yahoo.com - January 23 at 9:32 AM
Reviewing Allena Pharmaceuticals (ALNA) & ZIOPHARM Oncology (ZIOP)Reviewing Allena Pharmaceuticals (ALNA) & ZIOPHARM Oncology (ZIOP)
www.americanbankingnews.com - January 23 at 1:18 AM
Zacks: Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 Earnings Per ShareZacks: Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 Earnings Per Share
www.americanbankingnews.com - January 23 at 1:18 AM
ZIOPHARM Oncology (ZIOP) Stock Rating Reaffirmed by Zacks Investment ResearchZIOPHARM Oncology (ZIOP) Stock Rating Reaffirmed by Zacks Investment Research
www.americanbankingnews.com - January 13 at 4:08 PM
BidaskClub Downgrades ZIOPHARM Oncology (ZIOP) to Strong SellBidaskClub Downgrades ZIOPHARM Oncology (ZIOP) to Strong Sell
www.americanbankingnews.com - January 12 at 12:40 AM
Active-Investors: Blog Exposure - ZIOPHARM Updated on Key Clinical Programs and Corporate Development ActivitiesActive-Investors: Blog Exposure - ZIOPHARM Updated on Key Clinical Programs and Corporate Development Activities
www.finanznachrichten.de - January 11 at 11:00 AM
Blog Exposure - ZIOPHARM Updated on Key Clinical Programs and Corporate Development ActivitiesBlog Exposure - ZIOPHARM Updated on Key Clinical Programs and Corporate Development Activities
finance.yahoo.com - January 11 at 11:00 AM
Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare ConferenceZiopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 9 at 10:28 AM
Zacks: Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) Will Announce Quarterly Sales of $1.59 MillionZacks: Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) Will Announce Quarterly Sales of $1.59 Million
www.americanbankingnews.com - January 7 at 8:04 AM
Zacks Investment Research Upgrades ZIOPHARM Oncology (ZIOP) to BuyZacks Investment Research Upgrades ZIOPHARM Oncology (ZIOP) to Buy
www.americanbankingnews.com - January 6 at 5:46 PM
Zacks: Brokerages Expect ZIOPHARM Oncology Inc. (ZIOP) Will Announce Earnings of -$0.13 Per ShareZacks: Brokerages Expect ZIOPHARM Oncology Inc. (ZIOP) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - January 5 at 11:22 PM
ZIOPHARM Oncology (ZIOP) Stock Rating Lowered by ValuEngineZIOPHARM Oncology (ZIOP) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 31 at 11:04 PM
ZIOPHARM Oncology Inc. (ZIOP) Given Consensus Rating of "Hold" by BrokeragesZIOPHARM Oncology Inc. (ZIOP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 30 at 1:50 AM
ETFs with exposure to ZIOPHARM Oncology, Inc. : December 28, 2017ETFs with exposure to ZIOPHARM Oncology, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:18 PM
ZIOPHARM Oncology (ZIOP) & Its Rivals Critical ReviewZIOPHARM Oncology (ZIOP) & Its Rivals Critical Review
www.americanbankingnews.com - December 28 at 1:13 PM
Reviewing ZIOPHARM Oncology (ZIOP) and Its CompetitorsReviewing ZIOPHARM Oncology (ZIOP) and Its Competitors
www.americanbankingnews.com - December 28 at 8:48 AM
ZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017ZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 1:22 PM
Reviewing ZIOPHARM Oncology (ZIOP) and The CompetitionReviewing ZIOPHARM Oncology (ZIOP) and The Competition
www.americanbankingnews.com - December 26 at 7:20 AM
Contrasting ZIOPHARM Oncology (ZIOP) & Its CompetitorsContrasting ZIOPHARM Oncology (ZIOP) & Its Competitors
www.americanbankingnews.com - December 23 at 11:22 PM
Comparing ZIOPHARM Oncology (ZIOP) and Its CompetitorsComparing ZIOPHARM Oncology (ZIOP) and Its Competitors
www.americanbankingnews.com - December 23 at 1:24 AM
ZIOPHARM to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)ZIOPHARM to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - December 22 at 6:24 PM
 Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) Will Post Quarterly Sales of $1.59 Million Brokerages Anticipate ZIOPHARM Oncology Inc. (ZIOP) Will Post Quarterly Sales of $1.59 Million
www.americanbankingnews.com - December 22 at 9:08 AM
ZIOPHARM Oncology (ZIOP) and Its Rivals Critical SurveyZIOPHARM Oncology (ZIOP) and Its Rivals Critical Survey
www.americanbankingnews.com - December 15 at 1:36 PM
ZIOPHARM Oncology (ZIOP) Given a $10.00 Price Target at HC WainwrightZIOPHARM Oncology (ZIOP) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 14 at 7:46 PM
ZIOPHARM Oncology Inc. (ZIOP) Short Interest Up 3.7% in NovemberZIOPHARM Oncology Inc. (ZIOP) Short Interest Up 3.7% in November
www.americanbankingnews.com - December 14 at 2:40 AM
ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting - GlobeNewswire (press release)ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting - GlobeNewswire (press release)
globenewswire.com - December 11 at 4:30 PM
ZIOPHARM Oncologys (ZIOP) "Hold" Rating Reiterated at Raymond James FinancialZIOPHARM Oncology's (ZIOP) "Hold" Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - December 11 at 11:50 AM
$1.59 Million in Sales Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter$1.59 Million in Sales Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter
www.americanbankingnews.com - December 4 at 6:56 AM
Short Interest in ZIOPHARM Oncology Inc (ZIOP) Decreases By 3.9%Short Interest in ZIOPHARM Oncology Inc (ZIOP) Decreases By 3.9%
www.americanbankingnews.com - November 28 at 2:04 AM
ZIOPHARM Oncology (ZIOP) Reports Positive Upadte Results of Ad-RTS-hIL-12 Study in Brain Cancer - SlideshowZIOPHARM Oncology (ZIOP) Reports Positive Upadte Results of Ad-RTS-hIL-12 Study in Brain Cancer - Slideshow
seekingalpha.com - November 23 at 6:26 PM
Ziopharm Oncology (ZIOP) Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at SNO MeetingZiopharm Oncology (ZIOP) Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at SNO Meeting
www.streetinsider.com - November 20 at 4:30 PM
Pre-Open Movers 11/20: (CZZ) (CAVM) (ZIOP) Higher; (BITA) (CAH) (MNST) Lower (more...) - StreetInsider.comPre-Open Movers 11/20: (CZZ) (CAVM) (ZIOP) Higher; (BITA) (CAH) (MNST) Lower (more...) - StreetInsider.com
www.streetinsider.com - November 20 at 12:31 PM
ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology ... - GlobeNewswire (press release)ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology ... - GlobeNewswire (press release)
globenewswire.com - November 20 at 12:31 PM
Ziopharm says its brain cancer drug helped trial patients live more than a yearZiopharm says its brain cancer drug helped trial patients live more than a year
finance.yahoo.com - November 20 at 12:31 PM
Ziopharm says its brain cancer drug helped trial patients live more than a yearZiopharm says its brain cancer drug helped trial patients live more than a year
finance.yahoo.com - November 20 at 12:31 PM
Call to feature key neuro-oncology thought leadersCall to feature key neuro-oncology thought leaders
www.nasdaq.com - November 18 at 10:36 AM

SEC Filings

ZIOPHARM Oncology (NASDAQ:ZIOP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ZIOPHARM Oncology (NASDAQ:ZIOP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ZIOPHARM Oncology (NASDAQ ZIOP) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.